SCHEMBL4306235

SCHEMBL4306235

CC(C)(C)OC(=O)N1CCC(N(Cc2ccc(C(F)(F)F)cc2)c2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
PTPRB P23467 1/20 0.52
PTPN11 Q06124 1/20 0.52
GPR119 Q8TDV5 4/20 0.52
JAK2 O60674 1/20 0.52
JAK1 P23458 1/20 0.52
TGFBR1 P36897 1/20 0.51
KDM4E B2RXH2 1/20 0.49
PKM P14618 1/20 0.49
TACR1 P25103 3/20 0.47
STS P08842 1/20 0.47
CCR5 P51681 1/20 0.47
MAPT P10636 1/20 0.47
USP30 Q70CQ3 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4303459 0.91 GPR119 (0.51) MEN1KMT2AGPR119JAK2JAK1
SCHEMBL4309355 0.91 MEN1 (0.57) MEN1KMT2APTPRBPTPN11GPR119
SCHEMBL4310460 0.91 MEN1 (0.57) MEN1KMT2APTPRBPTPN11GPR119
SCHEMBL4302437 0.90 TGFBR1 (0.50) MEN1KMT2APTPRBPTPN11GPR119
SCHEMBL4306650 0.90 MEN1 (0.52) MEN1KMT2APTPRBPTPN11GPR119
SCHEMBL4306665 0.90 MEN1 (0.51) MEN1KMT2APTPRBPTPN11GPR119
SCHEMBL4306735 0.89 KMT2A (0.57) MEN1KMT2APTPRBPTPN11GPR119
SCHEMBL5969537 0.87 CCR5 (0.49) CCR5
SCHEMBL4309350 0.86 MEN1 (0.67) MEN1KMT2APTPRBPTPN11GPR119
SCHEMBL18263756 0.85 MEN1 (0.60) MEN1KMT2AGPR119TGFBR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488741-B2 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB PHARMA, S.A. (BE) 2009-02-10 US claimed
EP-1556045-B1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB SA (BE) 2006-08-02 EP claimed
EP-1556045-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2005-07-27 EP claimed
WO-2004030668-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2004-04-15 WO claimed
US-7488741-B2 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB PHARMA, S.A. (BE) 2009-02-10 US disclosed
EP-1693061-A1 Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases UCB, S.A. (BE) 2006-08-23 EP disclosed
EP-1556045-B1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB SA (BE) 2006-08-02 EP disclosed
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB, S.A. (BE) 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments PNMT, HTR5A, HTR4 MEN1 4456/4885KMT2A 1360/4885PTPRB 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.